Physician profile
Patsy Ballard
NPI 1902969587
$864.65
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $519 · 2023: $99.71 · 2024: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $345.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $168.10 | 2023-2024 | |
| Astellas Pharma US INC | $99.00 | 2021 | |
| Amgen INC. | $74.43 | 2021 | |
| Lilly USA, LLC | $65.66 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $46.80 | 2021-2024 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $45.50 | 2021 | |
| Alkermes, INC. | $42.96 | 2023-2024 | Aristada, Vivitrol, Lybalvi |
| Pfizer INC. | $41.98 | 2021 | |
| Novo Nordisk INC | $33.29 | 2021 | |
| Lundbeck LLC | $32.75 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $31.22 | 2023 | |
| Tris Pharma INC | $30.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.90 | 2024 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $19.82 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.09 | 2024 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $17.40 | 2021 | |
| Glaxosmithkline, LLC. | $14.02 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.96 | 2023 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patsy Ballard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.